REPLICEL LIFE SCIENCES CON GAMEWhat is going on at Replicel is a con game.
There has been no news on progress related to the dermal injector in a full year. This withholding of information is most likely deliberate. The lack of information, along with the acceptance by the Board of the one-sided Offer To Purchase in March has caused the stock to slide to $0.02!
Andrew Schutte, CEO, with the help of the Board has put the small shareholders in a very bad situation. Either accept his Offer To Purchase and hope that he will honestly account for all future royaly and asset sales revenue (while further diluting the Company shares by converting worthless options into stock for his 'helpers') or reject the Offer To Purchase and see him convert his 2 million dollar loan into 100 million shares at $0.02 per share. The latter action will give him approximately 70% of the outstanding shares (120 million / 170 million). Either way he wins and we lose!